These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31055074)

  • 1. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
    J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract]   [Full Text] [Related]  

  • 2. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
    Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
    JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
    [No Abstract]   [Full Text] [Related]  

  • 3. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.
    Klempner SJ; Borghei A; Hakimian B; Ali SM; Ou SI
    J Thorac Oncol; 2017 Jan; 12(1):152-156. PubMed ID: 27693535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.
    Jiang W; Yang N; Zhang Y
    J Thorac Oncol; 2018 Jul; 13(7):e124-e126. PubMed ID: 29935852
    [No Abstract]   [Full Text] [Related]  

  • 10. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Guisier F; Piton N; Salaun M; Thiberville L
    Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
    Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
    [No Abstract]   [Full Text] [Related]  

  • 13. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
    Zhang Y; Yin J; Peng F
    Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
    Berger LA; Janning M; Velthaus JL; Ben-Batalla I; Schatz S; Falk M; Iglauer P; Simon R; Cao R; Forcato C; Manaresi N; Bramlett K; Buson G; Hanssen A; Tiemann M; Sauter G; Bokemeyer C; Riethdorf S; Reck M; Pantel K; Wikman H; Loges S
    J Thorac Oncol; 2018 Dec; 13(12):e243-e246. PubMed ID: 30205165
    [No Abstract]   [Full Text] [Related]  

  • 15. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
    Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
    [No Abstract]   [Full Text] [Related]  

  • 19. Crizotinib in
    Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
    Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of Wild-type
    Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
    Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.